Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $10.4 million.

  • Aligos Therapeutics' Shares Outstanding (Weighted Average) rose 6532.29% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 6532.29%. This contributed to the annual value of $6.3 million for FY2024, which is 14438.02% up from last year.
  • According to the latest figures from Q3 2025, Aligos Therapeutics' Shares Outstanding (Weighted Average) is $10.4 million, which was up 6532.29% from $6.3 million recorded in Q4 2024.
  • Aligos Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $156.4 million for Q2 2024, and its period low was $1.7 million during Q3 2023.
  • In the last 5 years, Aligos Therapeutics' Shares Outstanding (Weighted Average) had a median value of $42.4 million in 2021 and averaged $44.3 million.
  • In the last 5 years, Aligos Therapeutics' Shares Outstanding (Weighted Average) crashed by 9593.13% in 2023 and then soared by 26391.03% in 2024.
  • Aligos Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $39.9 million in 2021, then increased by 7.13% to $42.7 million in 2022, then plummeted by 94.0% to $2.6 million in 2023, then skyrocketed by 144.38% to $6.3 million in 2024, then surged by 65.53% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $6.3 million for Q4 2024, and $6.3 million during Q3 2024.